Imugene Limited (ASX: IMU) is an immuno-oncology company, which is into the clinical stage. The company is engaged in the operations of developing a range of new and novel immunotherapies that has an objective of activating the immune system of cancer patients so that tumours can be treated and abolished. The company uses its unique platform technology to control the immune system of the body to generate antibodies against tumours, which is potentially very effective.
The company today on 2 April 2019, announced that the new data on the KEY-Vaxx and B-Vaxx cancer vaccine program has been showcased by Dr. Tanios Bekaii at the American Association for Cancer Research in the 2019 Annual Meeting.
In the presentation of KEY-Vaxx, the highlights and key findings demonstrated that when KEY-Vaxx is combined with B-Vaxx, it is more effective in reducing tumour growth in a validated mouse model of colon carcinoma versus either the PD-1 KEY-Vaxx vaccine alone, or more importantly, the positive control gold standard anti-mouse PD-1 monoclonal antibody. The vaccine combination did not exhibit either toxicity or autoimmunity and was considered to be safe. The company is working to find out the potential effectiveness of KEY-Vaxx in treating a range of cancers.
KEY-Vaxx is a B-cell peptide cancer vaccine. This is used for treating tumours, including lung cancer. Phase 1 trial of the B-Vaxx consisted of a study of the best dose of vaccine therapy and the side effects in treating patients.
The company also today presented new data on the Phase Ib study of its HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 Annual Meeting in Atlanta, Georgia, USA.
The presentation of the poster (abstract number 8249) was given by Professor Ursula Wiedermann from the Medical University Vienna, who is the lead inventor of the HER-Vaxx cancer vaccine and a member of Imugene’s Scientific Advisory Board, together with a reputed research team at the Medical University Vienna.
As per the Managing Director and Chief Executive Officer, Leslie Chong, the company is encouraged by the overall positive data from the Phase Ib trial, which supports the B-cell platform cancer vaccine strategy of the company for treating HER-2 positive gastric cancer.
Among the key highlights, Professor Wiedermann highlighted that 11 of 14 patients were evaluable for vaccine-specific immune responses and tumour response assessment. Among the three evaluable patients treated at the highest dose of 50 micrograms in cohort 3, all showed a partial response with two demonstrating greater than 40% reduction in the tumour size from baseline to day 56. The patients in cohort 3, who received the highest dose of 50 micrograms recorded high antibody levels, which are correlated with the clinical responses and reduction in the tumour size.
On the price-performance front, the stock of Imugene Limited was trading at $0.020, with a market capitalisation of ~$72.2 million (AEST 02:29 PM). The stock has generated a YTD return of 11.11% and generated a negative return of 4.76% over the past six months. Its 52-week high price stands at $0.039, and 52-week low price stands at $0.015 with an average trading volume of ~ 3,655,947.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.